These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 37540803

  • 1. Tumor-Targeted Nonablative Radiation Promotes Solid Tumor CAR T-cell Therapy Efficacy.
    Quach HT, Skovgard MS, Villena-Vargas J, Bellis RY, Chintala NK, Amador-Molina A, Bai Y, Banerjee S, Saini J, Xiong Y, Vista WR, Byun AJ, De Biasi A, Zeltsman M, Mayor M, Morello A, Mittal V, Gomez DR, Rimner A, Jones DR, Adusumilli PS.
    Cancer Immunol Res; 2023 Oct 04; 11(10):1314-1331. PubMed ID: 37540803
    [Abstract] [Full Text] [Related]

  • 2. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
    Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M.
    Sci Transl Med; 2014 Nov 05; 6(261):261ra151. PubMed ID: 25378643
    [Abstract] [Full Text] [Related]

  • 3. Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors.
    Tomar S, Zhang J, Khanal M, Hong J, Venugopalan A, Jiang Q, Sengupta M, Miettinen M, Li N, Pastan I, Ho M, Hassan R.
    Mol Cancer Ther; 2022 Jul 05; 21(7):1195-1206. PubMed ID: 35499461
    [Abstract] [Full Text] [Related]

  • 4. Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects.
    Zhu Y, Wang K, Yue L, Zuo D, Sheng J, Lan S, Zhao Z, Dong S, Hu S, Chen X, Feng M.
    Pharmacol Res; 2024 May 05; 203():107186. PubMed ID: 38641176
    [Abstract] [Full Text] [Related]

  • 5. Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer.
    Zhu Y, Zuo D, Wang K, Lan S, He H, Chen L, Chen X, Feng M.
    J Cancer Res Clin Oncol; 2023 Nov 05; 149(16):15027-15038. PubMed ID: 37612388
    [Abstract] [Full Text] [Related]

  • 6. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.
    Hung CF, Xu X, Li L, Ma Y, Jin Q, Viley A, Allen C, Natarajan P, Shivakumar R, Peshwa MV, Emens LA.
    Hum Gene Ther; 2018 May 05; 29(5):614-625. PubMed ID: 29334771
    [Abstract] [Full Text] [Related]

  • 7. Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models.
    Goto S, Sakoda Y, Adachi K, Sekido Y, Yano S, Eto M, Tamada K.
    Cancer Immunol Immunother; 2021 Sep 05; 70(9):2503-2515. PubMed ID: 33559069
    [Abstract] [Full Text] [Related]

  • 8. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.
    Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, Kalos M, June CH.
    Cancer Immunol Res; 2014 Feb 05; 2(2):112-20. PubMed ID: 24579088
    [Abstract] [Full Text] [Related]

  • 9. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor.
    Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, Predina J, Powell DJ, Riley JL, June CH, Albelda SM.
    Clin Cancer Res; 2011 Jul 15; 17(14):4719-30. PubMed ID: 21610146
    [Abstract] [Full Text] [Related]

  • 10. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
    Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, Keith B, Young RM, Engels B, Sorsa S, Siurala M, Havunen R, Tähtinen S, Hemminki A, June CH.
    JCI Insight; 2018 Apr 05; 3(7):. PubMed ID: 29618658
    [Abstract] [Full Text] [Related]

  • 11. Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors.
    Ding J, Guyette S, Schrand B, Geirut J, Horton H, Guo G, Delgoffe G, Menk A, Baeuerle PA, Hofmeister R, Tighe R.
    Oncoimmunology; 2023 Apr 05; 12(1):2182058. PubMed ID: 36875551
    [Abstract] [Full Text] [Related]

  • 12. Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies.
    Hu ZI, Ghafoor A, Sengupta M, Hassan R.
    Cancer; 2021 Apr 01; 127(7):1010-1020. PubMed ID: 33620732
    [Abstract] [Full Text] [Related]

  • 13. Proton radiation boosts the efficacy of mesothelin-targeting chimeric antigen receptor T cell therapy in pancreatic cancer.
    Amit U, Uslu U, Verginadis II, Kim MM, Motlagh SAO, Diffenderfer ES, Assenmacher CA, Bicher S, Atoche SJ, Ben-Josef E, Young RM, June CH, Koumenis C.
    Proc Natl Acad Sci U S A; 2024 Jul 30; 121(31):e2403002121. PubMed ID: 39047033
    [Abstract] [Full Text] [Related]

  • 14. Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers.
    O'Hara MH, Stashwick C, Plesa G, Tanyi JL.
    Immunotherapy; 2017 Aug 30; 9(9):767-780. PubMed ID: 28771103
    [Abstract] [Full Text] [Related]

  • 15. Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model.
    Wang Y, Wang J, Yang X, Yang J, Lu P, Zhao L, Li B, Pan H, Jiang Z, Shen X, Liang Z, Liang Y, Zhu H.
    Front Immunol; 2021 Aug 30; 12():628906. PubMed ID: 33777013
    [Abstract] [Full Text] [Related]

  • 16. A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab.
    Adusumilli PS, Zauderer MG, Rivière I, Solomon SB, Rusch VW, O'Cearbhaill RE, Zhu A, Cheema W, Chintala NK, Halton E, Pineda J, Perez-Johnston R, Tan KS, Daly B, Araujo Filho JA, Ngai D, McGee E, Vincent A, Diamonte C, Sauter JL, Modi S, Sikder D, Senechal B, Wang X, Travis WD, Gönen M, Rudin CM, Brentjens RJ, Jones DR, Sadelain M.
    Cancer Discov; 2021 Nov 30; 11(11):2748-2763. PubMed ID: 34266984
    [Abstract] [Full Text] [Related]

  • 17. Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors.
    Morello A, Sadelain M, Adusumilli PS.
    Cancer Discov; 2016 Feb 30; 6(2):133-46. PubMed ID: 26503962
    [Abstract] [Full Text] [Related]

  • 18. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.
    Liu G, Zhang Q, Li D, Zhang L, Gu Z, Liu J, Liu G, Yang M, Gu J, Cui X, Pan Y, Tian X.
    Hum Immunol; 2021 Feb 30; 82(2):130-138. PubMed ID: 33341289
    [Abstract] [Full Text] [Related]

  • 19. Breaking through the treatment desert of conventional mesothelin-targeted CAR-T cell therapy for malignant mesothelioma: A glimpse into the future.
    Wang Y, Zhao G, Xing S, Wang S, Li N.
    Pharmacol Res; 2024 Jun 30; 204():107220. PubMed ID: 38768670
    [No Abstract] [Full Text] [Related]

  • 20. Mesothelin-targeted CAR-T cell therapy for solid tumors.
    Klampatsa A, Dimou V, Albelda SM.
    Expert Opin Biol Ther; 2021 Apr 30; 21(4):473-486. PubMed ID: 33176519
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.